Skip to main content
TrimSoMoEverything GLP-1, in one place
← FDA Warning Letters Register
Factual Data Summary

GLP-1 FDA Warning Letters 2023–2026: Data Summary

Factual counts and distributions across all 162 official FDA warning letters concerning compounded, unapproved, or misbranded GLP-1 receptor agonists published on FDA.gov through late 2026.

Download CSV dataset (162 records)Fields: Company Name, Date, Medications, Violation Categories, FDA Original URL

Key findings from the dataset

  • •Recent enforcement concentration: Letters from 2025 and 2026 account for 92.0% (149 of 162) of all GLP-1 warning letters in the dataset, with 78 letters issued in 2026 alone.
  • •Semaglutide is the most frequently cited medication: Named in 146 of 162 letters (90.1%), followed by Tirzepatide in 111 letters (68.5%) and Retatrutide in 18 letters (11.1%).
  • •Misbranding is the leading violation category: Cited in 153 of 162 letters (94.4%), followed by false or misleading marketing claims (117 letters, 72.2%) and unapproved new drug allegations (62 letters, 38.3%). (Note: Violation categories are assigned by TrimSoMo's classification rules (see methodology), not by FDA.)
  • •Telehealth providers are the most common recipients: Telehealth entities received 110 of 162 letters (67.9%), followed by facilities/clinics (22 letters, 13.6%) and online pharmacies (13 letters, 8.0%).

Letters by Calendar Year

YearLettersShare (%)
20267848.1%
20257143.8%
2024116.8%
202321.2%
Total162100.0%

Letters by Medication Named

Letters citing multiple medications are counted in each category

MedicationLettersInvolved in (%)
Semaglutide15495.1%
Tirzepatide11369.8%
Retatrutide2314.2%
Liraglutide53.1%
Mazdutide42.5%
Cagrilintide31.9%
Survodutide21.2%
Lixisenatide10.6%

Letters by Violation Category

Letters may cite multiple statutory violations

Note: Violation categories are assigned by TrimSoMo's classification rules (see methodology), not by FDA.

Violation CategoryLettersInvolved in (%)
Misbranding14589.5%
False or misleading claims11470.4%
Unapproved new drug6640.7%
CGMP / insanitary conditions169.9%
Compounding outside 503A / 503B4326.5%
Other regulatory violations3924.1%

Letters by Recipient Entity Type

Entity TypeLettersShare (%)
Telehealth11067.9%
Other Facility2213.6%
Online / Internet Pharmacy138.0%
Manufacturer / API84.9%
Compounding Pharmacy84.9%
Compounding pharmacy10.6%
Total162100.0%
Citation & Licensing

How to cite this dataset

TrimSoMo GLP-1 FDA Warning Letter Dataset (2023–2026). Published by TrimSoMo. Available at: https://trimsomo.com/fda-warning-letters/report/. Data compiled from official U.S. FDA warning letters (FDA.gov).

License: Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). You are free to share and adapt this summary for non-commercial research, reporting, or academic purposes with appropriate attribution to TrimSoMo.